Licochalcone F alleviates glucose tolerance and chronic inflammation in diet-induced obese mice through Akt and p38 MAPK

Clinical Nutrition

Volumn 35, Issue 2, 2016, Pages 414-421

  Bak, Eun Jung ^a   Choi, Kyung Chul ^b   Jang, Sungil ^a,c   Woo, Gye Hyeong ^d   Yoon, Ho Geun ^e   Na, Younghwa ^f   Yoo, Yun Jung ^a,c   Lee, Youngseok ^g   Jeong, Yangsik ^h   Cha, Jeong Heon ^a,c  

^a Yonsei University College of Dentistry   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Yonsei University   (South Korea)

^d Semyung University   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f CHA University   (South Korea)

^g Kookmin University   (South Korea)

^h Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Anti inflammatory effect; Diet induced obese mice; Licochalcone F; Obesity induced chronic inflammation

Indexed keywords

CD68 ANTIGEN; CHALCONE DERIVATIVE; CYCLOOXYGENASE 2; FAT DROPLET; GLYCOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LICOCHALCONE F; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CCL2 PROTEIN, MOUSE; GLUCOSE BLOOD LEVEL; NOS2 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL SIZE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIET INDUCED OBESITY; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; FATTY LIVER; FOOD INTAKE; GENE EXPRESSION; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE MIGRATION; MALE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; WEIGHT GAIN; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ADVERSE EFFECTS; ANIMAL; BODY WEIGHT; C57BL MOUSE; CHRONIC DISEASE; DOWN REGULATION; DRUG EFFECTS; GENETICS; GLUCOSE BLOOD LEVEL; INFLAMMATION; LIPID DIET; MACROPHAGE; METABOLISM; MOUSE MUTANT; OBESITY;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; BODY WEIGHT; CHALCONES; CHEMOKINE CCL2; CHRONIC DISEASE; CYCLOOXYGENASE 2; DIET, HIGH-FAT; DOWN-REGULATION; GLUCOSE INTOLERANCE; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; OBESITY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84960479783     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2015.03.005     Document Type: Article

References (32)

1. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801.
2. Camp H.S., Ren D., Leff T. Adipogenesis and fat-cell function in obesity and diabetes. Trends Mol Med 2002, 8:442-447.
3. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 2005, 115:1111-1119.
4. Di Gregorio G.B., Yao-Borengasser A., Rasouli N., Varma V., Lu T., Miles L.M., et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005, 54:2305-2313.
5. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
6. Coenen K.R., Gruen M.L., Chait A., Hasty A.H. Diet-induced increases in adiposity, but not plasma lipids, promote macrophage infiltration into white adipose tissue. Diabetes 2007, 56:564-573.
7. Matafome P., Louro T., Rodrigues L., Crisostomo J., Nunes E., Amaral C., et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev 2011, 27:54-62.
8. Ghanim H., Dhindsa S., Aljada A., Chaudhuri A., Viswanathan P., Dandona P. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab 2006, 91:3553-3558.
9. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004, 89:2728-2735.
10. Weisberg S.P., Leibel R., Tortoriello D.V. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008, 149:3549-3558.
11. Kang J.H., Goto T., Han I.S., Kawada T., Kim Y.M., Yu R. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet. Obes Silver Spring 2010, 18:780-787.
12. Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi 2000, 120:849-862.
13. Nomura T., Fukai T. Phenolic constituents of licorice (Glycyrrhiza species). Fortschr Chem Org Naturst 1998, 73:1-158.
14. Na Y., Cha J.H., Yoon H.G., Kwon Y. A concise synthesis of licochalcone E and its regio-isomer, licochalcone F. Chem Pharm Bull Tokyo 2009, 57:607-609.
15. Yoo J.Y., Choi K.C., Kang H., Kim Y.J., Lee J., Jun W.J., et al. Histone deacetylase 3 is selectively involved in L3MBTL2-mediated transcriptional repression. FEBS Lett 2010, 584:2225-2230.
16. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264.
17. de Souza C.J., Eckhardt M., Gagen K., Dong M., Chen W., Laurent D., et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001, 50:1863-1871.
18. Guri A.J., Hontecillas R., Si H., Liu D., Bassaganya-Riera J. Dietary abscisic acid ameliorates glucose tolerance and obesity-related inflammation in db/db mice fed high-fat diets. Clin Nutr 2007, 26:107-116.
19. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
20. Rhee S.D., Kim C.H., Park J.S., Jung W.H., Park S.B., Kim H.Y., et al. Carbenoxolone prevents the development of fatty liver in C57BL/6-Lep ob/ob mice via the inhibition of sterol regulatory element binding protein-1c activity and apoptosis. Eur J Pharmacol 2012, 691:9-18.
21. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
22. Fain J.N., Bahouth S.W., Madan A.K. TNFalpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord 2004, 28:616-622.
23. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995, 95:2409-2415.
24. Kim C.S., Park H.S., Kawada T., Kim J.H., Lim D., Hubbard N.E., et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes Lond 2006, 30:1347-1355.
25. Pietilainen K.H., Kannisto K., Korsheninnikova E., Rissanen A., Kaprio J., Ehrenborg E., et al. Acquired obesity increases CD68 and tumor necrosis factor-alpha and decreases adiponectin gene expression in adipose tissue: a study in monozygotic twins. J Clin Endocrinol Metab 2006, 91:2776-2781.
26. Welsh G.I., Hers I., Berwick D.C., Dell G., Wherlock M., Birkin R., et al. Role of protein kinase B in insulin-regulated glucose uptake. Biochem Soc Trans 2005, 33:346-349.
27. Shao J., Yamashita H., Qiao L., Friedman J.E. Decreased Akt kinase activity and insulin resistance in C57BL/KsJ-Leprdb/db mice. J Endocrinol 2000, 167:107-115.
28. Sartori R., Li F., Kirkwood K.L. MAP kinase phosphatase-1 protects against inflammatory bone loss. J Dent Res 2009, 88:1125-1130.
29. Koistinen H.A., Chibalin A.V., Zierath J.R. Aberrant p38 mitogen-activated protein kinase signalling in skeletal muscle from Type 2 diabetic patients. Diabetologia 2003, 46:1324-1328.
30. Montessuit C., Rosenblatt-Velin N., Papageorgiou I., Campos L., Pellieux C., Palma T., et al. Regulation of glucose transporter expression in cardiac myocytes: p38 MAPK is a strong inducer of GLUT4. Cardiovasc Res 2004, 64:94-104.
31. Brown A.E., Palsgaard J., Borup R., Avery P., Gunn D.A., De Meyts P., et al. p38 MAPK activation upregulates proinflammatory pathways in skeletal muscle cells from insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol Metab 2015, 308:E63-E70.
32. Carlson C.J., Koterski S., Sciotti R.J., Poccard G.B., Rondinone C.M. Enhanced basal activation of mitogen-activated protein kinases in adipocytes from type 2 diabetes: potential role of p38 in the downregulation of GLUT4 expression. Diabetes 2003, 52:634-641.